Advertisement

Etoposide phosphate

  • Ines Mader
  • Patrizia E. Fürst-Weger
  • Robert M. Mader
  • Elisabeth I. Semenitz
  • Robert Terkola
  • Sabine M. Wassertheurer

Keywords

Public Health Internal Medicine Product Characteristic General Measure Recommended Treatment 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Secondary literature

  1. [1]
    Bristol-Myers Squibb, personal communication, January 1999.Google Scholar
  2. [2]
    Summary of product characteristics Etopophos® (Germany), Bristol-Myers Squibb, July 1999.Google Scholar
  3. [3]
    Summary of product characteristics Etopofos® (Austria), Bristol-Myers Squibb, June 2000.Google Scholar
  4. [4]
    Hande KR: Etoposide: four decades of development of a topoisomerase II inhibitor. Eur J Cancer 43: 1514–1521, 1998.CrossRefGoogle Scholar

Copyright information

© Springer-Verlag Wien 2003

Authors and Affiliations

  • Ines Mader
    • 1
  • Patrizia E. Fürst-Weger
    • 2
  • Robert M. Mader
    • 3
  • Elisabeth I. Semenitz
    • 4
  • Robert Terkola
    • 5
  • Sabine M. Wassertheurer
    • 6
  1. 1.Austrian Breast and Colorectal Cancer Study GroupViennaAustria
  2. 2.SMZ FloridsdorfKrankenhaus und GeriatriezentrumViennaAustria
  3. 3.Clinical Division of Oncology, Department of Medicine IUniversity HospitalViennaAustria
  4. 4.AnstaltsapothekeLandeskrankenhaus — Universitätskliniken InnsbruckAustria
  5. 5.Kaiser-Franz-Josef HospitalViennaAustria
  6. 6.Apotheke LKH-Univ.-Klinikum GrazAustria

Personalised recommendations